Document 0029
 DOCN  M95B0029
 TI    HIV-1 recombinant gp160 vaccine induced antibodies in serum and saliva.
       The NIAID AIDS Vaccine Clinical Trials Network.
 DT    9511
 AU    Gorse GJ; Rogers JH; Perry JE; Newman FK; Frey SE; Patel GB; Belshe RB;
       Division of Infectious Diseases, Saint Louis University Health; Sciences
       Center, MO 63110-0250, USA.
 SO    Vaccine. 1995 Feb;13(2):209-14. Unique Identifier : AIDSLINE
       MED/95351033
 AB    As part of a phase I safety and immunogenicity trial of a
       vaccinia-expressed HIV-1 recombinant gp160 (rgp160) candidate vaccine,
       we measured serum and saliva antibody responses in low risk, uninfected
       volunteers. Six healthy adult volunteers received 50 micrograms doses of
       rgp160 vaccine adjuvanted in alum and deoxycholate at months 0, 1, 6,
       and 12. A 200 micrograms rgp160 immunization was given to four
       volunteers at 18 months. The vaccine induced anti-envelope glycoprotein
       IgG and IgA serum antibodies in all six volunteers. Saliva antibodies to
       envelope glycoprotein appeared in some volunteers at certain timepoints.
       Three volunteers appeared to transiently develop vaccine-induced
       secretory IgA antibody to envelope glycoprotein in whole saliva.
 DE    Adjuvants, Immunologic/ADMINISTRATION & DOSAGE/PHARMACOLOGY  Adolescence
       Adult  Alum Compounds/ADMINISTRATION & DOSAGE  AIDS
       Vaccines/ADMINISTRATION & DOSAGE/*PHARMACOLOGY  Deoxycholic
       Acid/ADMINISTRATION & DOSAGE  Gene Products, env/*IMMUNOLOGY  Human  HIV
       Antibodies/*BIOSYNTHESIS/*BLOOD  HIV-1/*IMMUNOLOGY
       IgA/BIOSYNTHESIS/BLOOD  IgG/BIOSYNTHESIS/BLOOD  Middle Age  Protein
       Precursors/*IMMUNOLOGY  Saliva/*IMMUNOLOGY/*VIROLOGY  Support, U.S.
       Gov't, P.H.S.  Vaccines, Synthetic/ADMINISTRATION & DOSAGE/PHARMACOLOGY
       JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).